As drugs, devices and other healthcare products become more innovative and complex, and as development costs increase, working collaboratively becomes more important.
According to analysts at RBC Capital Markets, Sarepta Therapeutics, Sage Therapeutics and Loxo Oncology are the most likely takeover targets among biotechnology firms in 2019, reported Investor's Business Daily. Sarepta is working on a gene therapy in a m
The UK pharmaceutical industry is pressing ahead with M&A activity and is “geared to weather any disruption due to Brexit”, suggest results of a recent survey by EY.